Robert V. House, M.S.P.H., Ph.D., DVC President
Robert V. House is president of DynPort Vaccine Company LLC, a biotechnology firm that manages product development programs for U.S. Government agencies and provides consulting, technical and program management services to companies in the biotechnology and pharmaceutical industries.
DVC's portfolio includes vaccines and therapeutics to protect against emerging infectious diseases including biological warfare threat agents and seasonal and pandemic influenza. The company's biodefense programs include vaccines for plague, tularemia and botulinum neurotoxin. DVC's experience includes:
- Alternative vaccine delivery systems
- Biological and chemical defense
- Biolgocial therapeutics
- Emerging infectious diseases
- Live attenuated vaccines
- Recombinant vaccines
- Therapeutic polyclonal antibodies
Prior to joining DVC, which is based in Frederick, Md., Dr. House worked at Covance Laboratories in Madison, Wis., and IIT Research Institute in Chicago, Ill., where he managed highly successful programs in immunotoxicology assessment. He has more than 20 years of experience in biomedical research and development, specializing in the assessment of inadvertent and therapeutic immunomodulation. Dr. House earned his Master of Science in Public Health in Parasitology and Laboraty Practice and his Ph.D. in Medical Parasitology from the University of North Carolina at Chapel Hill School of Public Health. He is the author or co-author of more than 100 journal articles, book chapters and books covering immunology, immunotoxicology, infectious disease and biodefense, and has participated in numerous working groups and expert panels in the field of immunotoxicology. He is a frequent speaker at conferences and educational seminars.
Related Links
Read Q&A with Dr. House about biodefense and industry trends.
Contact us to request Dr. House or another DVC expert as a speaker for industry events.